Myasthenia Gravis Program

The Myasthenia Gravis Program, established in 1990, is the only such program in the area. Myasthenia Gravis is an auto-immune disease involving the thymus gland in which 85% of patients have antibodies to muscle acetylcholine receptors (AchR-Ab) that interfere with neuromuscular transmission and can cause sometimes life-threatening weakness. Patients are often treated with immunosuppressive drugs, plasma exchange and intravenous immunoglobulin.

We are currently participating in an NIH (National Institutes of Health) sponsored study which is a multi-center, multiracial, international, single-blinded clinical trial that aims to answer the best treatment options for myasthenia gravis patients.